|
WBPhenotype:0001871
|
drug induced life span variant
|
Life span of the animal is not influenced by drug exposure in the same manner as control animals. |
|
WBPhenotype:0001872
|
drug induced locomotion variant
|
Locomotion of the animal is not influenced by drug exposure in the same manner as control animals. |
|
WBPhenotype:0001101
|
egg laying response to drug variant
|
Characteristic response to drugs with respect to egg-laying behavior varies compared to control. |
|
WBPhenotype:0000011
|
drug resistant
|
Animals fail to respond to the concentration of a drug that elicits a response in control animals. Alternatively, animals require increased concentration or longer exposure to this compound to elicit the response compared to control animals. Animals are not affected by exposure to the drug. |
|
WBPhenotype:0000010
|
drug hypersensitive
|
Animals respond to a specific drug at a lower concentration or a shorter exposure compared to control animals. |
|
WBPhenotype:0000845
|
levamisole response variant
|
Animals exhibit variations in the response to the addition of levamisole compared to that observed in control animals. Levamisole is a cholinergic agonist. |
|
WBPhenotype:0001573
|
nicotine response variant
|
Animals exhibit variations in the response to the addition of nicotine compared to that observed in control animals. Nicotine is a cholinergic agonist. |
|
WBPhenotype:0002109
|
drug susceptible
|
Animals are affected by exposure to the drug. |
|
WBPhenotype:0000681
|
DMPP response variant
|
Animals exhibit variations in their response to DMPP compared to that observed in control animals. |
|
WBPhenotype:0000359
|
tunicamycin response variant
|
Animals exhibit variations in the response to the addition of tunicamycin compared to that observed in control animals. Tunicamycin induces the unfolded protein response. |
|
WBPhenotype:0001842
|
drug withdrawal response variant
|
Any variation in the state or activity of an organism as a result of abrupt discontinuation or decreased dosage of a drug, compared to control. |
|
WBPhenotype:0001232
|
serotonin response variant
|
Animals exhibit variations in the response to the addition of serotonin compared to that observed in control animals. Serotonin is a monoamine neurotransmitter. |
|
WBPhenotype:0000555
|
drug adaptation variant
|
Animals show variations in their decreased responsiveness after prolonged or repeated exposure to a drug compared to that in control. |
|
WBPhenotype:0001854
|
benomyl response variant
|
Animals exhibit variations in their response to the microtubule-depolymerizing drug benomyl, compared to that observed in control animals. |
|
WBPhenotype:0001856
|
ivermectin response variant
|
Animals exhibit variations in their response to ivermectin, an agonist of glutamate-gated chloride channels, compared to that observed in control animals. |
|
WBPhenotype:0001783
|
ligand gated channel activity variant
|
Animals exhibit variations in the actions of a channel that catalyses the transmembrane transfer of a cation when acetylcholine has been bound by the channel complex or one of its constituent parts compared to control animals. |
|
WBPhenotype:0002058
|
pore forming toxin response variant
|
Animals are not affected to the same degree as control animals under similar conditions of pore forming toxin exposure. |
|
WBPhenotype:0002047
|
muscimol response variant
|
Animals exhibit variations in their response to muscimol compared to that observed in control animals. Muscimol is a GABA-A receptor agonist. |
|
WBPhenotype:0000558
|
calcium channel modulator response variant
|
Animals exhibit variations in their response to specific calcium channel modulators compared to that observed in control animals. |
|
WBPhenotype:0002049
|
abamectin repsonse variant
|
Animals are not affected to the same degree as control animals under similar conditions of abamectin exposure. |
|
WBPhenotype:0001290
|
acetylcholinesterase inhibitor response variant
|
Animals exhibit variations in their response to a specific acetylcholinesterase inhibitor compared to that observed in control animals. |
|
WBPhenotype:0002384
|
xenotoxicity suppressor
|
Animals are resistant to the toxicity of an anti-infective xenobiotic such as R24. Such small molecules protect the host from bacterial infection by inducing antibacterial immune responses via the p38 MAPK pathway. These molecules tend to have toxic effects in addition to immunostimulatory activity. |
|
WBPhenotype:0001878
|
hydroxyurea response variant
|
Animals exhibit variations in the response to the addition of hydroxyurea compared to that observed in control animals. Hydroxyurea stops DNA from being replicated. |
|
WBPhenotype:0001337
|
adrenergic receptor antagonist response variant
|
Animals exhibit variations in their response to a specific adrenergic receptor antagonist compared to that observed in control animals. |
|
WBPhenotype:0001614
|
anticonvulsant response variant
|
Animals exhibit variations in their response to a specific anticonvulsant compared to that observed in control animals. |
|
WBPhenotype:0001598
|
inhibitor of serotonin uptake variant
|
Treatment with inhibitors of serotonin reuptake does not elicit the same response as observed for control animals. |
|
WBPhenotype:0000627
|
anesthetic response variant
|
Animals exhibit variations in their response to a specific anesthetic compared to that observed in control animals. |
